Fonar settles patent case with Toshiba
Fonar and Toshiba Corp. have settled their pending litigation over MRI patent claims, the companies reported this month. As part of the settlement, Toshiba made a monetary payment of an unspecified amount to Fonar, of Melville, NY. Neither company
Fonar and Toshiba Corp. have settled their pending litigation over MRI patent claims, the companies reported this month. As part of the settlement, Toshiba made a monetary payment of an unspecified amount to Fonar, of Melville, NY. Neither company admitted liability in the settlement, which included cross-licensing arrangements.
The litigation was part of Fonars ongoing effort to assert its patent claims against other MRI vendors, a campaign that has resulted in monetary payments from GE, Hitachi, Philips, and Siemens. Fonar and Toshiba had filed claims against each other in U.S. District Courts in New York and California.
In other Fonar news, the company reported third-quarter financial results (end-March) of $7.1 million, up 60% compared with $4.4 million in the same period a year ago. Fonars net loss was $3.7 million, compared with $5.7 million in the third quarter of 1997.
Much of the revenue growth was due to Fonars acquisition activities in physician practice management, a new business for the company. Meanwhile, revenues in the firms MRI equipment business were flat for the first nine months of 1998: Fonar had $5.8 million in revenue from equipment sales and service in the period, matching sales in the same period in 1997.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
